PT  - JOURNAL ARTICLE
AU  - Jonathan Noujaim
AU  - Khin Thway
AU  - Cyril Fisher
AU  - Robin L. Jones
TI  - Dermatofibrosarcoma protuberans: from translocation to targeted therapy
AID  - 10.7497/j.issn.2095-3941.2015.0067
DP  - 2015 Dec 01
TA  - Cancer Biology and Medicine
PG  - 375--384
VI  - 12
IP  - 4
4099  - http://www.cancerbiomed.org/content/12/4/375.short
4100  - http://www.cancerbiomed.org/content/12/4/375.full
SO  - Cancer Biol Med2015 Dec 01; 12
AB  - Dermatofibrosarcoma protuberans (DFSP), the most common dermal sarcoma, is a low-grade, slow growing fibroblastic malignant neoplasm that most frequently affects middle aged adults and is characterized by a high local recurrence rate and a low propensity for metastasis. Wide surgical resection or Mohs micrographic surgery (MMS) are the preferred approaches for localized disease, while radiation therapy is warranted for inoperable disease or for cases with positive margins where re-excision is not possible. DFSP is generally regarded as refractory to conventional chemotherapy. Treatment options for systemic disease were limited until the discovery of a unique translocation, t(17;22)(q22;q13) (COL1A1;PDGFB) found in a majority of cases. In recent years, imatinib, a PDGFβR, ABL and KIT inhibitor, has revolutionized systemic therapy in DFSP. In this review, we summarize the epidemiological, clinical, histological and genetic characteristics of DFSP and update the readers on its current management.